Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study
Authors:
- Luís Henrique Wolff GowdakLGLuís Henrique Wolff Gowdak
- Paulo Magno Martins DouradoPDPaulo Magno Martins Dourado
- Dalton Bertolim PrécomaDPDalton Bertolim Précoma
- César de Oliviera Lopes DusilekCDCésar de Oliviera Lopes Dusilek
- Francisco Maia da SilvaFSFrancisco Maia da Silva
- Juan Carlos Yugar-ToledoJYJuan Carlos Yugar-Toledo
- Felipe Montes PenaFPFelipe Montes Pena
- Elizabeth Do Espírito Santo CestárioECElizabeth Do Espírito Santo Cestário
- Conrado Roberto Hoffmann FilhoCFConrado Roberto Hoffmann Filho
Open Access
- 29 April 2025
- journal article
- research article
- Published by Springer Nature in Cardiology and Therapy
- Vol. 14 (2) , 249-265
Abstract
Introduction The V-GOOD study evaluated the effectiveness of trimetazidine modified-release (MR) 80 mg once daily (OD) in patients with chronic coronary syndrome (CCS) who remained symptomatic despite antianginal therapies in routine clinical practice. Methods This prospective, observational study involved 1026 adult outpatients with symptomatic CCS from 70 sites in Brazil who were prescribed trimetazidine MR 80 mg OD plus background antianginal treatment. Data on number of angina attacks, short-acting nitrate consumption, prevalence of angina-free patients, severity of angina, patient-reported daily physical activity impairment, treatment adherence, tolerability, and cardiologist and patient satisfaction were collected at baseline (V1), then at 1 month (V2) and 3 months (V3). Results Following the addition of trimetazidine MR 80 mg OD, the mean ± standard deviation number of angina attacks per week decreased from 3.1 ± 2.8 at V1 to 1.0 ± 2.1 at V2, and 0.7 ± 1.7 at V3, with concurrent reductions in short-acting nitrate consumption, patient-reported daily physical activity impairment and the proportion of patients with limiting angina (Canadian Cardiovascular Society class III or IV), and increases in the proportion of angina-free patients (all p < 0.001 vs. V1). Most cardiologists rated trimetazidine MR 80 mg OD as satisfactory/very satisfactory (90.7% for effectiveness and 94.8% for tolerability); most patients rated the treatment schedule as convenient/very convenient (97.2%) and satisfactory/very satisfactory (97.1%). Treatment was well tolerated. Conclusions These data support the symptomatic benefits and good tolerability associated with adding trimetazidine MR 80 mg OD to other antianginal therapies in patients with persistent symptoms. Graphical abstract available for this article. Trial registration number NCT06464276. Graphical AbstractKeywords
Funding Information
- Servier Brazil
This publication has 34 references indexed in Scilit:
- Ischemia with No Obstructive Arteries (INOCA): A Review of the Prevalence, Diagnosis and ManagementCurrent Problems in Cardiology, 2022
- Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational StudyCardiology and Therapy, 2021
- Trimetazidine in cardiovascular medicineInternational Journal of Cardiology, 2019
- Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World PracticeAdvances in Therapy, 2018
- Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina PectorisCardiology and Therapy, 2018
- Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta-regression analysisInternational Journal of Cardiology, 2016
- Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failureInternational Journal of Cardiology, 2016
- The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trialsInternational Journal of Cardiology, 2014
- Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link!JACC, 2012
- The Prevalence of Weekly Angina Among Patients With Chronic Stable Angina in Primary Care PracticesArchives of internal medicine (1960), 2009